![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Summit Therapeutics Inc | NASDAQ:SMMT | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.01 | 0.11% | 9.48 | 9.52 | 9.75 | 1,045 | 12:32:19 |
Summit will host a conference call the same day at 1:00pm BST / 8:00am EDT. Conference call information will be included in the full year results press release and a replay of the call will also be available through the Company’s website, www.summitplc.com.
About Summit TherapeuticsSummit is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
Summit Therapeutics | |
Glyn Edwards / Richard Pye (UK office) | Tel: +44 (0)1235 443 951 |
Erik Ostrowski / Michelle Avery (US office) | +1 617 225 4455 |
Cairn Financial Advisers LLP | |
(Nominated Adviser) | |
Liam Murray / Tony Rawlinson | Tel: +44 (0)20 7148 7900 |
N+1 Singer | |
(Broker) | |
Aubrey Powell / Jen Boorer | Tel: +44 (0)20 7496 3000 |
MacDougall Biomedical Communications | |
(US media contact) | Tel: +1 781 235 3060 |
Chris Erdman / Karen Sharma | cerdman@macbiocom.com |
Consilium Strategic Communications | |
(Financial public relations, UK) | Tel: +44 (0)20 3709 5700 |
Mary-Jane Elliott / Sue Stuart / | summit@consilium-comms.com |
Jessica Hodgson / Lindsey Neville |
- END -
1 Year Summit Therapeutics Chart |
1 Month Summit Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions